European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
-
Abstract
-
To report a case of complex odontoid fracture malunion accompanied by atlantoaxial dislocation which was treated with a new surgical approach. ⋯ Anterior submandibular retropharyngeal odontoid osteotomy and posterior atlantoaxial fusion fixation is an effective method for treating IAAD associated with odontoid fracture malunion, it avoids the adverse effects of anterior transoral odontoid osteotomy and provides a new option for the treatment of odontoid fracture malunion associated with atlantoaxial dislocation.
-
Review Case Reports
Invasive intramedullary melanotic schwannoma: case report and review of the literature.
Melanotic schwannoma (MS) is rare, accounting for less than 1% of primary peripheral nerve sheath tumors, and most often occurs in the paraspinal nerve roots. Intramedullary MS is exceedingly rare, and to the best of our knowledge, only nine cases have been reported in literature. ⋯ Intramedullary MS' behavior is unpredictable and can have an aggressive clinical course such as recurrence and metastasis.
-
Review Case Reports
Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas.
Aneurysmal bone cysts (ABCs) of spine are conventionally treated with en-bloc resection or intralesional excision/curettage and reconstruction or filling of defects with bone cement. For the treatment of upper cervical ABCs, en-bloc resections are often not desirable considering the risk/benefit ratio while the risk of recurrence after intralesional excision is high. Hence, alternative management options are often necessary. We describe our clinical experience with one such treatment alternative-denosumab for the treatment of ABC of Atlas. ⋯ Our case report contributes to the accruing evidence on the effectiveness of denosumab for the treatment of spinal ABCs. However, long-term safety, risk of recurrence, optimal duration of treatment and consistency of denosumab are yet to be determined.